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Abstract. The hyperimmunoglobulinaemia D and per­
iodic fever (hyper-IgD) syndrome is typified by recur­
rent unpredictable febrile attacks with abdominal 
pain, joint involvement (arthralgias/arthritis), head­
ache, skin lesions and a polyclonal elevation of serum 
IgD (> 100 U m L” 1). Interferon-gamma (IFN-7 ) is a 
major proinflammatory cytokine which could play a 
role in the pathogenesis of the attacks. There is a need 
for parameters (if possible non-invasive) to monitor 
disease activity. A potential candidate is neopterin 
which is released by monocytes/macrophages when 
stimulated with IFN-7 , excreted unchanged in urine, 
and appears to be an early and sensitive marker for 
activation of the immune system. We measured rectal 
body temperature, serum IFN-7 , and urine neopterin 
in 10 hyper-IgD patients both during and between 
attacks. The body temperature rose to a mean of 
38,9°C  on the first day of the attack and normalized 
within 5 days. Serum IF N -7 during the first day of the 
attack was 2-98 IU  mL"1 and was significantly lower 
during remissions. The urine neopterin excretion was 
268 ± 170 ¿¿molmol"1 creatinine between attacks and 
was significantly increased to 638 ± 275 ¿anolmol-1 
creatinine on the first day of symptoms. Maximal 
urine neopterin values were reached on the fourth 
day of the attack (1051 ±  387 ¿zmolmor1 creatinine) 
and excretion gradually declined and attained values 
below 400 (jmolmol”1 creatinine after 9 days. There 
was a good correlation between serum IF N -7 and 
urine neopterin. The increases in serum IF N -7 and 
urine neopterin suggest activation of the cellular 
immunity during the febrile attacks of the hyper-IgD 
syndrome. Furthermore, the activation of the cellular 
immune system appears to persist several days after 
normalization of the body temperature. The signifi­
cant correlation between IF N -7 and urine neopterin in
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the hyper-IgD syndrome accords with experimental 
data suggesting that IF N -7 is the dominant factor in 
the release of neopterin. Our study shows that urinary 
neopterin is a good quantitative and qualitative para­
meter to monitor disease activity in patients with the 
hyper-IgD syndrome
Keywords. Hyper-IgD syndrome, interferon-gamma, 
urine neopterin.
Introduction
The hyperimmunoglobulinaemia D  and periodic fever 
syndrome (hyper-IgD) is characterized by recurrent 
attacks of fever associated with persistently elevated 
polyclonal serum IgD levels (> 100 U m L” 1)- [1] An 
autosomal recessive inheritance is typical [2]. Symp­
toms commence at an early age and persist through­
out life and the febrile attacks occur every 4-8 weeks, 
lasting 3-7 days. During these episodes the patients 
may suffer from abdominal distress (vomiting, 
diarrhoea and. pain), skin lesions, joint involvement, 
headache and lymphadenopathy [3,4], The cause of 
the syndrome is unknown but since attacks are 
featured by an important inflammatory reaction, 
IF N -7 as a major proinflammatory cytokine could 
play a role in the pathogenesis. Therefore, we 
measured IF N -7 as well as neopterin, a pteridine 
derivative, which is released by monocytes/macro­
phages when stimulated with IF N -7 [5], Neopterin, 
is conveniently excreted in urine and can be measured 
easily. It appears to be an early and sensitive marker 
of activation of the immune system [6]. In inflamma­
tory diseases such as rheumatoid arthritis and sys­
temic lupus erythematosus urinary neopterin levels 
correlate closely with the disease activity [7,8]. The 
present study investigates whether IF N -7 and urine 
neopterin are increased during the febrile attacks of 
the hyper-IgD syndrome and assesses the clinical
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Days after onset attack
Figure 1. The rectal body temperature in 10 patients in the first days after onset of an attack. Data are expressed as mean and 
standard deviation of mean. There is a normalization of the body temperature 5 days after the start of the attack.
utility of urinary neopterin as marker of disease 
activity in these patients.
Patients and methods
Patients
Ten patients, six female and four male, with the hyper- 
IgD syndrome were included in the study and the 
diagnosis of hyper-IgD syndrome was made accord­
ing to standard criteria [3]. The mean age at time of 
sampling was 28-8 years (range 8-61 years). Patients 
were instructed to commence sampling on the first day 
of the attack and to continue until the fever had 
subsided, with a maximum of 10 days sampling. 
Each day the first morning urine specimen was 
sampled in a special container, shielded from light, 
and frozen at -20°C  until analysis. The rectal body 
temperature was measured daily, using a digital ther­
mometer. Samples for urine neopterin concentrations 
were obtained in each patient between attacks to 
give baseline values. Sampling of serum for IF N -7  
measurements was performed on the first day of the 
attack and during remission.
Laboratory measurements
The IFN -7 concentration was determined by a com­
mercially available immunoradiometric assay. (Med- 
genix, Amersfoort, the Netherlands), The microtitre 
plate wells are coated with monoclonal anti IFN-7 . 
After washing, radiolabelled (123I) anti-IFN -7 was 
added. Bound radioactivity was determined in a 
gamma counter and the IF N -7 concentrations were 
calculated from standard curves. The lower limit of 
detection of the assay was 0*2 IU m L -1. The mean 
value obtained in healthy controls is 0-55 ±  0T4 
lU m L "1 (manufacturer’s information). 
Determination of neopterin was by reversed-phase
high-performance liquid chromatography with minor 
modifications [9]. Briefly, urine samples were centri­
fuged to remove debris, diluted in 1 to 10 with water 
containing dimethylpterine as an internal standard 
and injected directly onto a Techsphere 5 ODS 
column (HPLC Technology Ltd). A binary gradient 
elution was used with an initial mobile phase of 2%  
methanol in 15 inm olL-1 phosphate buffer, pH 6*4, 
increasing to 25% methanol after 12min, and creati­
nine was detected separately using a kinetic alkaline 
picrate (Jaffe) method. The ratio of neopterin to 
creatinine was calculated to compensate for variations 
of urine density. The median urine neopterin value for 
a group of 65 healthy controls was 149/imolmol“ 1 
creatinine (range 62-273) [8].
Statistical analysis
The paired non-parametric Wilcoxon test was used 
for statistical comparison of values obtained during 
active disease compared to remission values. Prob­
ability (P) values were calculated on the basis of two- 
tailed tests. A correlation coefficient was calculated 
with the Pearson’s correlation test. A P  value of 
<0*05 considered to be the lowest level of signifi­
cance. Data are given in mean ±  standard deviation,
Results
The attacks in the hyper-IgD were featured by an 
increase of the mean body temperature to 38*9°C on 
the first day of the attack which returned to normal by 
day 5 (Fig. 1).
Serum for IFN -7 measurements was obtained from 
nine patients during an attack. The IF N -7 concentra­
tion during the first day of the attack was 2'98 ±  3*55 
(median 1*33) IU m L ' 1 and was significantly lower, 
0*59 ±  0-39 (median 0*44) IU  m L“ 1 during remissions 
(Fig. 2). For 10 hyper-IgD patients a total 69 urine
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Figure 2. The left panel refers to the individual concentrations of circulating IFN -7 in nine patients during and in between 
attacks of the hyper-IgD syndrome. The mean and standard error of the mean are displayed at either side. IFN -7 
concentrations were significantly higher during active disease compared to remission (P < 0-05). The right panel indicates 
the individual urine neopterin values for 10 patients between and during attacks of the hyper-IgD syndrome. The mean and 
standard error of the mean are displayed at either side. Note the significant elevation of urine neopterin during attacks 
(P - 0-002).
samples (mean 6-9 per patient) were collected during 
attacks. Three patients collected the complete set of 
urine samples for the 10 days. The control urine 
neopterin excretion for the 10 patients was 268 ± 
170 (median 199) ¿miolmol-1 creatinine, significantly 
lower than values obtained on the first day of symp­
toms: 638 ± 275 (median 604) /¿molmol“1 creatinine 
(Fig. 2) (P = 0-002). A ll patients had higher total 
urine neopterin during attacks compared to between 
attacks. The mean urine neopterin increased in the 
first days of the attack and maximal values were 
reached on the fourth day of the attack (1051 ± 
387^molmol“ 1 creatinine). The urine neopterin 
gradually declined and attained values below 
400/Limolmol"1 creatinine after 9 days (Fig. 3). One 
patient started sampling 2 days before the onset of the 
febrile attack. In the days preceeding the attack 
neopterin excretion values were 245 and 
280^molmol“ 1 creatinine. The excretion increased 
respectively to 345 and 780 ¿¿molmol”1 creatinine 
on the first 2 days of the febrile attack. There was a 
good correlation between serum IFN -7 and urine 
neopterin excretion; r = 0*6675 (P < 0*05). The 
decrease in body temperature and thus the end of an 
attack, anticipated the decrease of urine neopterin by 
4-5 days. In five patients the activation of the cellular 
immune system (urine neopterin > 200 ¿¿molmol~l 
creatinine) persisted during remission despite 
apparent clinical well-being.
Discussion
Serum concentrations of IF N -7 and urine excretion of 
neopterin correlated well with the clinical condition of
the hyper-IgD patients. IF N -7 increased fivefold over 
remission values during active disease. IF N -7 partici­
pates in the human inflammatory response, partly 
through its ability to induce production of T N Fa  
and other cytokines [10]. IF N -7 itself may be a 
pyrogenic compound, but its presence does not 
explain all signs and symptoms in the hyper-IgD 
syndrome [11], Other proinflammatory cytokines pos­
sibly involved in the pathogenesis are currently being 
studied by us. We found that urine neopterin values 
are low between attacks of the hyper-IgD syndrome 
but increase significantly during attacks. Neopterin is
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Figure 3. Urine neopterin in ¿¿molmol-1 creatinine ratios during the 
first 10 days of an attack in 10 patients with the hyper-IgD 
syndrome. Day 1 denotes the first day of the attack as defined by 
the symptoms. Data are expressed as mean and standard deviation.
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a non-specific marker of cellular activation being 
produced by human macrophages in response to 
IF N -7 [5]. Neopterin is a stable compound, readily 
detectable and easy to measure. Since neopterin is not 
metabolized, the urine excretion reflects the integrated 
release of neopterin [12]. Furthermore, serum IF N -7 
and urine neopterin correlate significantly in the 
hyper-IgD syndrome which is in line with these 
experimental data in vitro suggesting that IF N -7 is 
the dominant factor involved in the release of neop­
terin [5]. The course of the urine neopterin excretion 
during the attacks demonstrates that maximal values 
are attained within 4 days. Data from one patient 
indicate that neopterin excretion values are normal in 
the days immediately before an attack. This may 
suggest that the value of neopterin as a predictor of 
attacks is rather limited. The end of the attack, as 
indicated by the normalization of the rectal body 
temperature and disappearance of the symptoms 
occurs in 5 days, but at the same time urine neopterin 
still continued to be elevated above individual refer­
ence values. Thus, the activation of the cellular 
immune system appears to persist after normalization 
of the temperature.
Our study shows that urinary neopterin is a good 
quantitative and qualitative parameter to monitor 
disease activity in patients with the hyper-IgD syn­
drome. A reliable non-invasive parameter is needed in 
the management of the hyper-IgD syndrome because 
many patients are young ( < 10 years), and because of 
the outpatient basis of the treatment. Moreover, 
evaluation of drugs in a disorder characterized by 
unpredictable febrile attacks requires a dependable 
parameter. In studies evaluating the effect of colchi­
cine in familial Mediterranean fever, another periodic 
fever syndrome, patients were requested to keep 
records of their attacks with symptom diaries and/or 
postcards (to be sent to the investigators when having 
an attack) [13-15]. Symptom diaries depend to a large 
extent on self-interpretation by the patient and con­
sequently more objective and accurate parameters are 
clearly needed. The use of urine neopterin to monitor 
disease activity has great advantages; the patients can 
sample and store urine at home in their home freezer 
for up to 6 months contrasting with serum that 
requires processing.
In conclusion, urine neopterin appears to be a good 
monitor of disease activity in the hyper-IgD syn­
drome, Neopterin measurements can be useful when 
evaluating the effect of therapy for the hyper-IgD 
syndrome. Our data suggest that attacks of the 
hyper-IgD syndrome are associated with macrophage 
activation as evidenced by increased serum IF N -7 and 
urine neopterin excretion.
Acknowledgment
J. P. H. Drenth is a recipient of a Dutch Organization 
for Scientific Research fellowship for Clinical Investi­
gators (KW O  900-716-065).
We are indebted to Johanna van der Ven-Jongek- 
rijg for the analysis of IFN-7 . We are grateful to Daan 
N. Drenth for his help with collecting the urine 
samples.
References
1 Van der Meer JWM, Vossen JM , Radi J  et al. Hyperimmuno- 
globulinemia D and periodic fever: A new syndrome. Lancet 
1984;i: 1087-90.
2 Drenth JPH, Mariman ECM, Van der Veide-Visser SD, Ropers 
HH, Van der Meer JW M  and the International Hyper-IgD 
Study Group. Location of the gene causing hyperimmunoglo- 
bulinemia D and periodic fever syndrome differs from that for 
familial mediterranean fever. Hum Genet 1994;94:616-20.
3 Drenth JPH, Haagsma CJ, Van der Meer JW M  and the Inter­
national Hyper-IgD Study Group. Hyperimmunoglobulinemia 
D and periodic fever. The clinical spectrum in a series of 50 
patients. Medicine (Baltimore) 1994;73:133-44.
4 Drenth JPH, Boom BW, Toonstra J, Van der Meer JW M  and 
the International Hyper-IgD Study Group. Cutaneous manifes­
tations and histologic findings in the hyperimmunoglobulinemia 
D syndrome. Arch Dermatol 1994;130:59-65.
5 Iiuber C, Batchelor JR, Fuchs D et al. Immune response- 
associated production of neopterin. Release from macrophages 
primarily under control of interferon gamma. J  Exp Med 
1984;160:310-16.
6 Wachter H, Fuchs D, Hausen A, Reibnegger G, Werner ER. 
Neopterin as marker for activation of cellular immunity: immu­
nological basis and clinical application. Adv Clin Chem 
1989;27:81-141.
7 Reibnegger G, Egg D, Fuchs D et al. Urinary neopterin reflects 
clinical activity in patients with rheumatoid arthritis. Arthritis
Rheum 1986;29:1063-70.
8 Lim K L, Jones AC, Brown NS, Powell RJ, Urine neopterin as a 
parameter of disease activity in patients with systemic lupus 
erythematosus: comparisons with serum sIL-2R and antibodies 
to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, 
and C3 degradation products. Ann Rheum Dis 1993;52:429-35.
9 Slazyk WE, Spierto FW. Liquid-chromatographic measurement 
of biopterin and neopterin in serum and urine. Clin Chem
1990;36:1364-8.
10 Farrar MA, Schreiber RD. The molecular cell biology of 
interferon-7 and its receptor. Ann Rev Immunol 1993; 11:571- 
611.
11 Dinarello CA, Cannon JG, Wolff SM. New concepts on the 
pathogenesis of fever. Rev Inf Dis 1988;10:168-89.
12 Fuchs D, Weiss G* Reibnegger G , Wachter H. The role of 
neopterin as a monitor of cellular immune activation in trans­
plantation, inflammatory, infectious and malignant diseases. 
Crit Rev Clin Lab Sci 1992;29:307-41.
13 Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Ailing DW. 
Colchicine therapy for familial Mediterranean fever. A double
blind trial. N Engl J  Med 1974;291:934-7.
14 Zemer D, Revach M, Pras M et a i A controlled trial of 
colchicine in preventing attacks of familial Mediterranean 
fever. N  Engl J  Med 1974;291:932-4.
15 Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in 
familial Mediterranean fever. A controlled double blind study. 
Ann Intern Med 1974;81:792-4.
© 1995 Blackwell Science Ltd, European Journal o f Clinical Investigation, 25, 683-686
